Radiofrequency ablation of renal cell carcinoma under CT guidance - Present and future status

Yasutomo Nasu, Yasuyuki Kobayashi, Katsutoshi Uematsu, Takashi Saika, Hiromi Kumon, Hideo Gobara, Hidefumi Mimura, Susumu Kanazawa

Research output: Contribution to journalArticle

Abstract

At Okayama University, radiofrequency ablation (RFA) of renal cell carcinoma was performed in May 2002 as the initial case in Japan. In 2004, it was regarded as an advanced medical technique by the Japanese authority. Since then, RFA has been actively performed for renal cell carcinoma not only at the primary site but also at the metastatic site, including the lung and bone. The clinical outcome has been compatible with other institutes and no serious adverse events have occurred. From the view paint of fusing technical innovation with medical safety, this treatment is a potent therapeutic option for renal cell carcinoma. In the era of laparoscopic surgery, RFA is indicated for cases with VHL, recurrence after partial nephrectomy, a single kidney and intolerance to general anesthesia, due to its technical advantage in that RFA can be repeated. In this review, the current clinical outcome is reported and future prospects are discussed as to whether it can be the safest and most concrete treatment for renal cell carcinoma in the 21st century.

Original languageEnglish
Pages (from-to)223-227
Number of pages5
JournalNishinihon Journal of Urology
Volume73
Issue number5
Publication statusPublished - May 20 2011

Fingerprint

Renal Cell Carcinoma
Paint
Nephrectomy
Laparoscopy
General Anesthesia
Japan
Kidney
Safety
Bone and Bones
Recurrence
Lung
Therapeutics

Keywords

  • Lung metastasis
  • Renal cell carcinoma
  • RFA

ASJC Scopus subject areas

  • Urology

Cite this

Radiofrequency ablation of renal cell carcinoma under CT guidance - Present and future status. / Nasu, Yasutomo; Kobayashi, Yasuyuki; Uematsu, Katsutoshi; Saika, Takashi; Kumon, Hiromi; Gobara, Hideo; Mimura, Hidefumi; Kanazawa, Susumu.

In: Nishinihon Journal of Urology, Vol. 73, No. 5, 20.05.2011, p. 223-227.

Research output: Contribution to journalArticle

@article{93e872a009434e1faeeda1c848a03085,
title = "Radiofrequency ablation of renal cell carcinoma under CT guidance - Present and future status",
abstract = "At Okayama University, radiofrequency ablation (RFA) of renal cell carcinoma was performed in May 2002 as the initial case in Japan. In 2004, it was regarded as an advanced medical technique by the Japanese authority. Since then, RFA has been actively performed for renal cell carcinoma not only at the primary site but also at the metastatic site, including the lung and bone. The clinical outcome has been compatible with other institutes and no serious adverse events have occurred. From the view paint of fusing technical innovation with medical safety, this treatment is a potent therapeutic option for renal cell carcinoma. In the era of laparoscopic surgery, RFA is indicated for cases with VHL, recurrence after partial nephrectomy, a single kidney and intolerance to general anesthesia, due to its technical advantage in that RFA can be repeated. In this review, the current clinical outcome is reported and future prospects are discussed as to whether it can be the safest and most concrete treatment for renal cell carcinoma in the 21st century.",
keywords = "Lung metastasis, Renal cell carcinoma, RFA",
author = "Yasutomo Nasu and Yasuyuki Kobayashi and Katsutoshi Uematsu and Takashi Saika and Hiromi Kumon and Hideo Gobara and Hidefumi Mimura and Susumu Kanazawa",
year = "2011",
month = "5",
day = "20",
language = "English",
volume = "73",
pages = "223--227",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "5",

}

TY - JOUR

T1 - Radiofrequency ablation of renal cell carcinoma under CT guidance - Present and future status

AU - Nasu, Yasutomo

AU - Kobayashi, Yasuyuki

AU - Uematsu, Katsutoshi

AU - Saika, Takashi

AU - Kumon, Hiromi

AU - Gobara, Hideo

AU - Mimura, Hidefumi

AU - Kanazawa, Susumu

PY - 2011/5/20

Y1 - 2011/5/20

N2 - At Okayama University, radiofrequency ablation (RFA) of renal cell carcinoma was performed in May 2002 as the initial case in Japan. In 2004, it was regarded as an advanced medical technique by the Japanese authority. Since then, RFA has been actively performed for renal cell carcinoma not only at the primary site but also at the metastatic site, including the lung and bone. The clinical outcome has been compatible with other institutes and no serious adverse events have occurred. From the view paint of fusing technical innovation with medical safety, this treatment is a potent therapeutic option for renal cell carcinoma. In the era of laparoscopic surgery, RFA is indicated for cases with VHL, recurrence after partial nephrectomy, a single kidney and intolerance to general anesthesia, due to its technical advantage in that RFA can be repeated. In this review, the current clinical outcome is reported and future prospects are discussed as to whether it can be the safest and most concrete treatment for renal cell carcinoma in the 21st century.

AB - At Okayama University, radiofrequency ablation (RFA) of renal cell carcinoma was performed in May 2002 as the initial case in Japan. In 2004, it was regarded as an advanced medical technique by the Japanese authority. Since then, RFA has been actively performed for renal cell carcinoma not only at the primary site but also at the metastatic site, including the lung and bone. The clinical outcome has been compatible with other institutes and no serious adverse events have occurred. From the view paint of fusing technical innovation with medical safety, this treatment is a potent therapeutic option for renal cell carcinoma. In the era of laparoscopic surgery, RFA is indicated for cases with VHL, recurrence after partial nephrectomy, a single kidney and intolerance to general anesthesia, due to its technical advantage in that RFA can be repeated. In this review, the current clinical outcome is reported and future prospects are discussed as to whether it can be the safest and most concrete treatment for renal cell carcinoma in the 21st century.

KW - Lung metastasis

KW - Renal cell carcinoma

KW - RFA

UR - http://www.scopus.com/inward/record.url?scp=79959476375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959476375&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 223

EP - 227

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 5

ER -